[Interferon-alpha therapy in hypernephroma].
The prognosis of metastatic renal cell cancer is unfavourable as neither chemo-, radiation- nor hormonal therapy achieve tumor remissions in more than 10% of the patients. Several methods of immunotherapy so far employed have not led to improved treatment results. However, with interferon (IFN) therapy--dependent on different prognostic factors--remissions in the range form 15 to 40% have been documented. The combination of IFN-alpha with vinblastine seems, according to some studies, to increase response rates. There is evidence that IFN-alpha in combination with IFN-gamma or interleukin-2 is more effective than monotherapy. New treatment possibilities are the combination of IFN with 5-fluorouracil or new cytokines.
Sagaster
K P
KP
I. Medizinischen Abteilung mit Onkologie, Wilhelminenspitals, Wien.
D002292:Carcinoma, Renal Cell / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D009362:Neoplasm Metastasis; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
D016898:Interferon-alpha; D007376:Interleukin-2; D014747:Vinblastine; D007371:Interferon-gamma; D005472:Fluorouracil
Interferon-alpha-Therapie beim Hypernephrom.